MCID: MGR001
MIFTS: 48

Migraine Without Aura

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Migraine Without Aura

MalaCards integrated aliases for Migraine Without Aura:

Name: Migraine Without Aura 12 6 44 15 17
Common Migraine 12 54 70
Migraine Without Aura, Susceptibility to 6

Classifications:



External Ids:

Disease Ontology 12 DOID:12783
ICD9CM 34 346.1
MeSH 44 D020326
NCIt 50 C117004
SNOMED-CT 67 56097005
ICD10 32 G43.0
UMLS 70 C0338480

Summaries for Migraine Without Aura

Disease Ontology : 12 A migraine that is characterized by migraine headaches that are not accompanied by an aura.

MalaCards based summary : Migraine Without Aura, also known as common migraine, is related to migraine, familial hemiplegic, 3 and headache. An important gene associated with Migraine Without Aura is MGR4 (Migraine, Susceptibility To, 4), and among its related pathways/superpathways are Circadian entrainment and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Milnacipran and Levomilnacipran have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and pituitary, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Migraine Without Aura

Diseases in the Migraine Without Aura family:

Migraine with or Without Aura 1 Migraine with or Without Aura 2
Migraine with or Without Aura 3 Migraine Without Aura 4
Migraine with or Without Aura 5 Migraine with or Without Aura 6
Migraine with or Without Aura 8 Migraine with or Without Aura 10
Migraine with or Without Aura 11 Migraine with or Without Aura 12
Migraine with or Without Aura 13

Diseases related to Migraine Without Aura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 migraine, familial hemiplegic, 3 31.4 SCN1A KCNK18 CACNA1A ATP1A2
2 headache 30.8 SLC6A4 SCN1A NOTCH3 CACNA1A ATP1A2
3 alexithymia 30.5 SLC6A4 HTR1A DRD2
4 generalized anxiety disorder 30.2 SLC6A4 HTR1A DRD2
5 sleep disorder 30.0 TNF SLC6A4 PRL HTR1A
6 familial hemiplegic migraine 29.8 SCN1A NOTCH3 KCNK18 CACNA1A ATP1A2
7 patent foramen ovale 29.7 SCN1A NOTCH3 MTHFR ATP1A2
8 panic disorder 29.5 SLC6A4 PRL HTR1A DRD4 DRD3 DRD2
9 restless legs syndrome 29.5 SLC6A4 PRL DRD4 DRD3 DRD2 CACNA1A
10 migraine with aura 29.4 TRPM8 SLC6A4 SCN1A PRDM16 NOTCH3 MTHFR
11 migraine, familial hemiplegic, 2 28.9 SCN1A KCNK18 CACNA1A ATP1A2 ASTN2
12 bipolar disorder 28.7 TNF SLC6A4 PRL MTHFR HTR1A DRD4
13 migraine with or without aura 1 27.9 TRPM8 TNF SLC6A4 SCN1A PRL PRDM16
14 migraine without aura 4 11.5
15 migraine with or without aura 13 11.2
16 carotidynia 10.9
17 ifap syndrome 2 10.7
18 polysubstance abuse 10.3 DRD3 DRD2
19 alcohol-induced mental disorder 10.3 SLC6A4 DRD2
20 cluster headache 10.3
21 tardive dyskinesia 10.3 DRD4 DRD3 DRD2
22 bestiality 10.3 DRD4 DRD3 DRD2
23 paraphilia disorder 10.3 SLC6A4 DRD4 DRD2
24 cyclothymic disorder 10.3 SLC6A4 DRD4 DRD2
25 oppositional defiant disorder 10.3 SLC6A4 DRD4 DRD2
26 heroin dependence 10.3 SLC6A4 DRD4 DRD2
27 allergic disease 10.3
28 cocaine dependence 10.2 SLC6A4 DRD3 DRD2
29 conduct disorder 10.2 SLC6A4 DRD4 DRD2
30 trigeminal neuralgia 10.2 TRPM8 SLC6A4 SCN1A
31 bulimia nervosa 10.2 SLC6A4 DRD4 DRD2
32 somatoform disorder 10.2 TRPM8 SLC6A4 SCN1A
33 drug dependence 10.2 SLC6A4 DRD3 DRD2
34 obsessive-compulsive personality disorder 10.2 SLC6A4 DRD3
35 galactorrhea 10.2 PRL DRD2
36 tic disorder 10.2 SLC6A4 DRD4 DRD3 DRD2
37 inhibited male orgasm 10.2 SLC6A4 HTR1A
38 opiate dependence 10.2 SLC6A4 DRD4 DRD3 DRD2
39 eating disorder 10.2 SLC6A4 DRD3 DRD2
40 prolactin producing pituitary tumor 10.2 PRL DRD2
41 motion sickness 10.2
42 hemophagocytic lymphohistiocytosis, familial, 5 10.2
43 endometriosis 10.2
44 substance dependence 10.2 SLC6A4 DRD4 DRD3 DRD2
45 cannabis abuse 10.2 HTR1A DRD4 DRD2
46 lingual-facial-buccal dyskinesia 10.2 HTR1A DRD3 DRD2
47 kleptomania 10.2 SLC6A4 HTR1A DRD2
48 substance-induced psychosis 10.1 SLC6A4 HTR1A DRD2
49 separation anxiety disorder 10.1 SLC6A4 HTR1A DRD4
50 paine syndrome 10.1 TRPM8 TNF SLC6A4 SCN1A

Comorbidity relations with Migraine Without Aura via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Migraine Without Aura:



Diseases related to Migraine Without Aura

Symptoms & Phenotypes for Migraine Without Aura

MGI Mouse Phenotypes related to Migraine Without Aura:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 ATP1A2 CACNA1A DRD2 DRD3 DRD4 HTR1A
2 homeostasis/metabolism MP:0005376 10.13 ATP1A2 CACNA1A DRD2 DRD3 DRD4 HTR1A
3 nervous system MP:0003631 10.06 ATP1A2 CACNA1A DRD2 DRD3 DRD4 HTR1A
4 integument MP:0010771 10.03 ASTN2 ATP1A2 CACNA1A DRD2 MTHFR NOTCH3
5 endocrine/exocrine gland MP:0005379 10.02 CACNA1A DRD2 FHL5 NOTCH3 PHACTR1 PRDM16
6 reproductive system MP:0005389 9.65 CACNA1A DRD2 FHL5 KCNK18 MTHFR NOTCH3
7 vision/eye MP:0005391 9.28 CACNA1A DRD3 DRD4 MEF2D MTHFR NOTCH3

Drugs & Therapeutics for Migraine Without Aura

Drugs for Migraine Without Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
2
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
3
Norepinephrine Approved Phase 4 51-41-2 439260
4
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
7
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9 Psychotropic Drugs Phase 4
10 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
11 Antidepressive Agents Phase 4
12 Gastrointestinal Agents Phase 4
13 Pharmaceutical Solutions Phase 4
14 Narcotics Phase 4
15 Dopamine Agents Phase 4
16 Dopamine Antagonists Phase 4
17 Neurotransmitter Agents Phase 4
18 Antiemetics Phase 4
19 Anesthetics, General Phase 4
20 Anesthetics, Intravenous Phase 4
21 Anticonvulsants Phase 4
22 Hypoglycemic Agents Phase 4
23 Serotonin Receptor Agonists Phase 4
24 Ketorolac Tromethamine Phase 4
25 Analgesics, Non-Narcotic Phase 4
26 Analgesics Phase 4
27 Antirheumatic Agents Phase 4
28 Cyclooxygenase Inhibitors Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Dexketoprofen trometamol Phase 4
32
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
33
Sumatriptan Approved, Investigational Phase 3 103628-46-2 5358
34
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
35
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
36
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
37
Promethazine Approved, Investigational Phase 3 60-87-7 4927
38
Rizatriptan Approved Phase 3 145202-66-0, 144034-80-0 5078
39
Caffeine Approved Phase 3 58-08-2 2519
40
Candesartan cilexetil Approved Phase 2, Phase 3 145040-37-5 2540
41
Angiotensin II Approved, Investigational Phase 2, Phase 3 68521-88-0, 11128-99-7, 4474-91-3 172198
42
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
43
Ergotamine Approved Phase 3 113-15-5 8223
44
Dihydroergotamine Approved, Investigational Phase 3 6190-39-2, 511-12-6 10531
45
Ketoprofen Approved, Vet_approved Phase 3 22071-15-4 3825
46
Candesartan Experimental Phase 2, Phase 3 139481-59-7 2541
47 Vasodilator Agents Phase 2, Phase 3
48 Phosphodiesterase Inhibitors Phase 3
49
Histamine Phosphate Phase 3 51-74-1 65513
50 Histamine H1 Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
2 Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial Completed NCT02314351 Phase 4 Metoclopramide 10 mg;Placebo;Fentanyl
3 TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study Completed NCT00212810 Phase 4 Topiramate
4 Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate) Completed NCT00210496 Phase 4 topiramate; almotriptan malate
5 Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
6 A Randomized-controlled Study; Comparison of the Effectiveness of Intravenous Ibuprofen and Intravenous Dexketoprofen in the Treatment of Migraine-related Headache in the Emergency Department Not yet recruiting NCT04533568 Phase 4 Ibuprofen 400 mg;Dexketoprofen
7 A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine Completed NCT00334178 Phase 3 Laxymig ER (drug)
8 A 12-week Prospective, Double-blinded, Randomized, Multicenter Study of Low Dose and Medium Dose Botulinum Toxin Type A (Dysport® ) Injection for Migraine Prophylaxis. Completed NCT00258609 Phase 3 Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection
9 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00236509 Phase 3 topiramate
10 A Multicentre, Dose Optimisation Study to Assess the Consistency of Efficacy of Eletriptan for the Treatment of Migraine (With and Without Aura) Completed NCT01859481 Phase 3 Placebo;Eletriptan HBr 40 mg;Eletriptan HBr 80 mg
11 EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Completed NCT03901482 Phase 3 Dihydroergotamine;Placebos
12 A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine Completed NCT00236561 Phase 3 topiramate, propranolol
13 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00231595 Phase 3 topiramate
14 Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial Completed NCT01814189 Phase 3 Sumatriptan+Promethazine (SPr)
15 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed NCT00471952 Phase 3 Maxalt 10mg MLT plus Caffeine 75mg;Maxalt 10mg MLT plus Placebo;Placebo + Placebo
16 Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study Completed NCT00884663 Phase 2, Phase 3 Candesartan;propranolol;placebo
17 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA* (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without Aura (ICHD-II 1.6.1) (*TREXIMET) Completed NCT00387881 Phase 3 sumatriptan succinate / naproxen sodium;Placebo
18 An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Recruiting NCT04406649 Phase 3 Dihydroergotamine
19 Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room Not yet recruiting NCT04726592 Phase 3 Clorazepate Dipotassium;Placebo;Ketoprofen;Metoclopramide
20 Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study Unknown status NCT00285402 Phase 2 AST-726 Low dose;AST-726 High dose;AST-726 Placebo
21 Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches. Unknown status NCT03220113 Phase 1, Phase 2
22 Multi-centre, Parallel Group, Double-blind, Placebo Controlled Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00311662 Phase 2 Tonabersat;Placebo
23 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache Completed NCT00123201 Phase 2 Dronabinol MDI
24 Effects of DFN-15 on Migraine With Allodynia Completed NCT03472378 Phase 2 DFN-15
25 Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura Completed NCT00959751 Phase 2 NXN-188;Placebo
26 Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension Completed NCT00534560 Phase 2 Tonabersat;Tonabersat;Placebo
27 A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine Terminated NCT00739024 Phase 2 Ramelteon;Placebo
28 A Randomized, Open-Label, Crossover Study to Evaluate the PK, Bioavailability, Dose Proportionality, Safety, and Tolerability of Single Doses of STS101, DHE Mesylate IM Injection and DHE Mesylate Nasal Spray in Healthy Adult Subjects Completed NCT03874832 Phase 1 Dihydroergotamine
29 Investigation of Vascular Inflammation in Migraine Without Aura Using Molecular Nano-imaging and Black Blood Imaging MRI Unknown status NCT02549898 Feraheme;Cilostazol
30 Multiparametric Diagnostic Model of Thick-section Clinical-quality MRI Data in Detecting Migraine Without Aura Unknown status NCT03570086
31 Cortical Reorganisation in Patients With Primary Headache Disorders Unknown status NCT00263991
32 Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI Unknown status NCT02202486
33 Mindfulness and Mechanisms of Pain Processing in Adults With Migraines Completed NCT02695498
34 Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Completed NCT04636359
35 Impact of a Nursing Intervention on the Clinical Evolution of Patients at a University Migraine Clinic Completed NCT01804517
36 The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients Completed NCT02364453 PACAP38
37 A Randomized, Double Blinded, Sham Controlled Clinical Study to Evaluate the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, for the Acute Treatment of Migraine Completed NCT03361423
38 The Effect of PACAP38 and VIP on Migraine Patients Assessed by a 3-Tesla MR Scanner Completed NCT01471990 Pituitary Adenylate Cyclase-Activating Polypeptide-38;Vasoactive Intestinal Peptide
39 Investigation of PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine Completed NCT03881644 Imigran
40 Basic Scientific Research Investigating PACAP38 Headache Inducing Effects in Migraine Patients Completed NCT00380263 PACAP38
41 Functional MRI (fMRI) in Patients With Migraine Without Aura Provoked by Completed NCT00363532 infusion of calcitonin gene related peptide (CGRP)
42 Evaluating the Prophylactic Efficacy of Acupuncture for Migraine Without Aura (MWoA) : A Randomized Controlled Trial Completed NCT02765581
43 CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load Completed NCT01924052 CGRP
44 Amylin and CGRP Migraine Provocation in Migraine Without Aura Patients Completed NCT03598075
45 Investigation of Serotonin Receptor Binding in the Migraine Brain Using Positron Emission Tomography Completed NCT02309606
46 Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option for Migraine? A Randomized Controlled Clinical Trial Completed NCT01741714
47 Continue or Stop Applying Wet Cupping (Al-Hijamah) in Migraine Headache: A Randomized Control Trial Completed NCT03479060
48 Glutamate Concentrations in the Brain Over the Course of a Migraine-like Attack Completed NCT04220606 Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)
49 A Continuous Study on Abiding Effect of Acupuncture for Migraine Treatment Completed NCT01687660
50 Pituitary Adenylate Cyclase-activating Polypeptide (PACAP27) Headache Properties in Migraine Without Aura Patients Completed NCT03471039 PACAP27;Saline

Search NIH Clinical Center for Migraine Without Aura

Cochrane evidence based reviews: migraine without aura

Genetic Tests for Migraine Without Aura

Anatomical Context for Migraine Without Aura

MalaCards organs/tissues related to Migraine Without Aura:

40
Brain, Cortex, Pituitary, Endothelial, Heart, Cerebellum, Thyroid

Publications for Migraine Without Aura

Articles related to Migraine Without Aura:

(show top 50) (show all 2208)
# Title Authors PMID Year
1
Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. 6 61
14718719 2004
2
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
3
Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. 6
16418737 2006
4
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 6
16865291 2006
5
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 6
14681301 2004
6
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 6
12746914 2003
7
Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. 6
12485196 2002
8
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. 6
11826025 2002
9
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 6
11896460 2002
10
Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. 6
11506397 2001
11
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 6
11261930 2001
12
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. 6
10450718 1999
13
Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. 6
9818939 1998
14
Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. 6
8056188 1994
15
CACNA1A gene non-synonymous single nucleotide polymorphisms and common migraine in Italy: a case-control association study with a micro-array technology. 54 61
19527141 2009
16
Analysis of chromosome 1 microsatellite markers and the FHM2-ATP1A2 gene mutations in migraine pedigrees. 61 54
16157018 2005
17
Absence of known familial hemiplegic migraine (FHM) mutations in the CACNA1A gene in patients with common migraine: implications for genetic testing. 54 61
12705332 2003
18
Suboccipital cerebrospinal fluid and plasma concentrations of somatostatin, neuropeptide Y and beta-endorphin in patients with common migraine. 54 61
1357579 1992
19
Association Between Hemostatic Profile and Migraine: A Mendelian Randomization Analysis. 61
33795393 2021
20
[Clinical and genetic analysis of 5 pediatric patients with hemiplegic migraine presenting as acute encephalopathy]. 61
33775052 2021
21
Headaches during pregnancy. 61
32838992 2021
22
Pediatric Episodic Migraine with Aura: A Unique Entity? 61
33802676 2021
23
The bottom-up approach: Non-invasive peripheral neurostimulation methods to treat migraine: A scoping review from the child neurologist's perspective. 61
33743386 2021
24
Atrial fibrillation and migraine with aura in young adults with ischemic stroke. 61
33200948 2021
25
Amylin analog pramlintide induces migraine-like attacks in patients. 61
33772845 2021
26
Retinal nerve fiber layer changes in migraine: a systematic review and meta-analysis. 61
33439389 2021
27
Glutamate levels and perfusion in pons during migraine attacks: A 3T MRI study using proton spectroscopy and arterial spin labeling. 61
32423331 2021
28
A resting-state functional MRI study in patients with vestibular migraine during interictal period. 61
33683634 2021
29
Common variants in KCNK5 and FHL5 genes contributed to the susceptibility of migraine without aura in Han Chinese population. 61
33762637 2021
30
Migraine: Calcium Channels and Glia. 61
33799975 2021
31
Impaired short-term visual paired associative plasticity in patients with migraine between attacks. 61
33136981 2021
32
Botulinum toxin as a novel therapeutic approach for auriculotemporal neuralgia. 61
33433917 2021
33
Cardiac sources of cerebral embolism in people with migraine. 61
32979886 2021
34
Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods. 61
32903061 2021
35
Visually guided associative learning in pediatric and adult migraine without aura. 61
32954816 2021
36
Association between Migraine and Cryptogenic Ischemic Stroke in Young Adults. 61
33078475 2021
37
Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study. 61
32955929 2021
38
Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. 61
33567890 2021
39
Supersaturation of VEP in Migraine without Aura Patients Treated with Topiramate: An Anatomo-Functional Biomarker of the Disease. 61
33671875 2021
40
Headache frequency associates with brain microstructure changes in patients with migraine without aura. 61
31898090 2021
41
Aberrant activity within auditory network is associated with psychiatric comorbidities in interictal migraineurs without aura. 61
33479923 2021
42
Altered Dynamic Amplitude of Low-Frequency Fluctuations in Patients With Migraine Without Aura. 61
33679354 2021
43
Migraine diagnosis and treatment: A knowledge and needs assessment of women's healthcare providers. 61
33377176 2021
44
Comparison of Effects and Brain-Gut Regulatory Mechanisms of Acupuncture and Flunarizine for Migraine: Study Protocol for a Randomized Controlled Trial. 61
33505495 2021
45
Neurophysiological correlates of abnormal auditory processing in episodic migraine during the interictal period. 61
32838536 2021
46
Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura. 61
32867533 2021
47
Migraine and cardiovascular risk factors: A clinic-based study. 61
33260087 2021
48
Serum lipid abnormalities in migraine: A meta-analysis of observational studies. 61
33398889 2021
49
The Altered Functional Connectivity With Pain Features Integration and Interaction in Migraine Without Aura. 61
33746709 2021
50
The epidemiology of primary headaches in patients with multiple sclerosis. 61
33295123 2021

Variations for Migraine Without Aura

ClinVar genetic disease variations for Migraine Without Aura:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NOTCH3 NM_000435.3(NOTCH3):c.505C>T (p.Arg169Cys) SNV Likely pathogenic 9219 rs28933696 GRCh37: 19:15302945-15302945
GRCh38: 19:15192134-15192134
2 TNF TNF, -308G-A SNV risk factor 12388 GRCh37:
GRCh38:

Expression for Migraine Without Aura

Search GEO for disease gene expression data for Migraine Without Aura.

Pathways for Migraine Without Aura

GO Terms for Migraine Without Aura

Cellular components related to Migraine Without Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.97 TRPM8 TNF SLC6A4 SCN1A NOTCH3 KCNK18
2 integral component of plasma membrane GO:0005887 9.56 TRPM8 TNF SLC6A4 KCNK18 HTR1A DRD4
3 synapse GO:0045202 9.23 SLC6A4 PHACTR1 MTHFR HTR1A DRD3 DRD2

Biological processes related to Migraine Without Aura according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.95 TRPM8 SCN1A CACNA1A ATP1A2
2 response to drug GO:0042493 9.94 SLC6A4 MTHFR DRD3 DRD2
3 sodium ion transmembrane transport GO:0035725 9.81 SLC6A4 SCN1A ATP1A2
4 cellular calcium ion homeostasis GO:0006874 9.8 TRPM8 DRD4 DRD3 DRD2
5 social behavior GO:0035176 9.75 SLC6A4 DRD4 DRD3
6 visual learning GO:0008542 9.73 DRD3 DRD2 ATP1A2
7 cation transmembrane transport GO:0098655 9.73 TRPM8 SCN1A CACNA1A ATP1A2
8 behavioral fear response GO:0001662 9.69 HTR1A DRD4 ATP1A2
9 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.65 DRD3 DRD2
10 vasoconstriction GO:0042310 9.65 SLC6A4 HTR1A
11 arachidonic acid secretion GO:0050482 9.65 DRD4 DRD3 DRD2
12 positive regulation of renal sodium excretion GO:0035815 9.63 DRD3 DRD2
13 G protein-coupled receptor internalization GO:0002031 9.63 DRD3 DRD2
14 negative regulation of protein secretion GO:0050709 9.63 DRD4 DRD3 DRD2
15 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.62 DRD4 DRD3
16 prepulse inhibition GO:0060134 9.62 DRD3 DRD2
17 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.61 DRD3 DRD2
18 regulation of dopamine metabolic process GO:0042053 9.61 HTR1A DRD4
19 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.6 DRD3 DRD2
20 behavioral response to ethanol GO:0048149 9.59 DRD4 DRD2
21 regulation of potassium ion transport GO:0043266 9.58 DRD3 DRD2
22 dopamine metabolic process GO:0042417 9.58 DRD4 DRD3 DRD2
23 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.57 DRD3 DRD2
24 regulation of locomotion involved in locomotory behavior GO:0090325 9.55 DRD3 DRD2
25 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.54 DRD4 DRD2
26 negative regulation of cytosolic calcium ion concentration GO:0051481 9.54 DRD3 DRD2 ATP1A2
27 acid secretion GO:0046717 9.52 DRD3 DRD2
28 behavioral response to cocaine GO:0048148 9.5 DRD4 DRD3 DRD2
29 synaptic transmission, dopaminergic GO:0001963 9.43 DRD4 DRD3 DRD2
30 negative regulation of voltage-gated calcium channel activity GO:1901386 9.33 DRD4 DRD3 DRD2
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.13 DRD4 DRD3 DRD2
32 response to histamine GO:0034776 8.8 DRD4 DRD3 DRD2

Molecular functions related to Migraine Without Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cation channel activity GO:0005261 9.33 TRPM8 SCN1A CACNA1A
2 serotonin binding GO:0051378 9.32 SLC6A4 HTR1A
3 dopamine binding GO:0035240 9.26 DRD4 DRD2
4 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD4 DRD3 DRD2
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.8 DRD4 DRD3 DRD2

Sources for Migraine Without Aura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....